Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
4 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Rivaroxaban prevents VTE after lower limb surgery

Roshini Claire Anthony
18 Apr 2020

Rivaroxaban reduced venous thromboembolism (VTE) risk without increasing bleeding compared with enoxaparin in patients who underwent lower limb nonmajor orthopaedic surgery, the PRONOMOS* trial showed.

“This study represents a major step forward in our treatment of patients after many orthopaedic procedures because it proves that we can more effectively prevent thrombosis with a once-daily oral medication versus a daily injection with the same safety,” said study investigator Dr Nadia Rosencher from Paris University, Paris, France, who presented the findings at ACC.20/WCC.

The study included 3,604 adults (median age 41 years) scheduled for nonmajor orthopaedic surgery of the lower limbs with planned immobilization (>15 days) who were at risk for VTE. They were randomized to receive once-daily doses of oral rivaroxaban (10 mg; n=1,809, 66 percent male) or subcutaneous enoxaparin (4,000 IU; n=1,795, 64 percent male) with corresponding placebos. Patients received the trial drug for a mean 28.6 days, with about 60 percent receiving treatment for 2 weeks to 1 month.

The most common surgeries were knee ligament repair, ankle fracture, and knee arthroscopy (37.0, 15.1, and 9.0 percent, respectively). Almost 14 percent of patients received pre-surgery prophylactic low-molecular-weight heparin (LMWH).

Major VTE** was significantly reduced in the rivaroxaban vs enoxaparin group (0.2 percent vs 1.1 percent; risk ratio [RR], 0.25, 95 percent confidence interval, 0.09–0.75; pnoninferiority<0.001; psuperiority=0.01). [ACC.20, abstract 20-LB-20404-ACC; N Engl J Med 2020;doi;10.1056/NEJMoa1913808]

This reduction was driven by a significant decrease in symptomatic VTE with rivaroxaban vs enoxaparin (0.2 percent vs 0.6 percent; RR, 0.28).

Median time to a VTE event was 26 and 40 days in the rivaroxaban and enoxaparin groups, respectively.

Bleeding – comprising major*** and nonmajor clinically relevant bleeding (NMCRB) – occurred at a comparable rate in the rivaroxaban and enoxaparin groups (1.1 percent vs 1.0 percent; RR, 1.04; p=0.89). This finding was consistent when bleeding type was assessed separately (major bleeding: 0.6 percent vs 0.7 percent; RR, 0.81; p=0.62; NMCRB: 0.5 percent vs 0.3 percent; RR, 1.48; p=0.46).

Post hoc analysis showed a 52 percent lower incidence of events in the rivaroxaban vs enoxaparin group (net clinical benefit outcome# 0.8 percent vs 1.8 percent).

Substantial variation exists in the guidelines on thromboprophylaxis for patients undergoing nonmajor orthopaedic surgery. The US guidelines do not recommend routine thromboprophylaxis, while the European guidelines recommend a personalized LMWH strategy in certain patient groups.

“In patients deemed at risk, rivaroxaban could replace LMWH to prevent VTE during postoperative reduced mobility after nonmajor orthopaedic surgery,” said Rosencher. However, further research is necessary to establish the patient subgroups who would derive the most benefit from thromboprophylaxis, said Rosencher and colleagues.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
4 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.